Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

2.

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.

Nandha R.

J Postgrad Med. 2012 Jul-Sep;58(3):203-6. Review.

3.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

4.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

5.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS.

Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Review.

6.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

7.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
8.

Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.

Pal SK, Twardowski P, Josephson DY.

Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Review.

PMID:
19733987
9.

[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].

Turitto G, Di Bisceglie M, Moraca L, Sasso N, Sepede C, Suriano A, Romito S.

Recenti Prog Med. 2012 Feb;103(2):74-8. doi: 10.1701/1045.11391. Review. Italian.

PMID:
22430753
10.

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.

Sonpavde G, Attard G, Bellmunt J, Mason MD, Malavaud B, Tombal B, Sternberg CN.

Eur Urol. 2011 Aug;60(2):270-8. doi: 10.1016/j.eururo.2011.04.032. Epub 2011 Apr 29. Review.

PMID:
21550166
11.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
12.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
13.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
14.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832
15.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
16.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Yin L, Hu Q.

Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Review.

PMID:
24276076
17.

Abiraterone in prostate cancer: a new angle to an old problem.

Stein MN, Goodin S, Dipaola RS.

Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Review.

18.

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G.

Future Oncol. 2010 May;6(5):665-79. doi: 10.2217/fon.10.48. Review. Erratum in: Future Oncol. 2011 May;7(5):695-6.

PMID:
20465382
19.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
20.

CYP17 inhibition as a hormonal strategy for prostate cancer.

Reid AH, Attard G, Barrie E, de Bono JS.

Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237. Review.

PMID:
18985049

Supplemental Content

Support Center